AbCellera Biologics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AbCellera Biologics generated cash of -$43,877,000, which is less than the previous year. Cash used in financing activities reached the amount of $10,356,000 last year. Net change in cash is therefore -$254,040,000.
Cash Flow
| 2018 | 3.56M | -5.30M | 12.18M |
|---|---|---|---|
| 2019 | 2.69M | -5.77M | 194.82K |
| 2020 | 22.69M | -119.78M | 683.65M |
| 2021 | 244.58M | -332.24M | -3.88M |
| 2022 | 277.36M | -352.62M | -1.62M |
| 2023 | -43.87M | -221.10M | 10.35M |
ABCL Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 414.65M | 501.14M | 594.11M | 7.55M | 10.44M | -283 |
Operating activities | ||||||
Net income | -146.39M | 158.51M | 153.46M | 118.91M | -2.21M | 309K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 30.89M | 33.10M | 17.25M | 5.27M | 1.84M | 918K |
Stock-based compensation expense | 64.18M | 49.48M | 30.64M | 8.39M | 890.23K | 615K |
| Deferred income tax benefit | 64.18M | 49.48M | 30.64M | 8.39M | 890.23K | 615K |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -45.93M | -22.71M | -37.38M | -5.46M | -1.80M | -477K |
Inventories | 18.25M | 0 | 40.91M | -134.34M | -150.09K | -897.77K |
Accounts payable | -15.10M | 1.06M | 1.4M | 6.60M | 150.09K | 180K |
Cash generated by operating activities | -43.87M | 277.36M | 244.58M | 22.69M | 2.69M | 3.56M |
Investing activities | ||||||
Purchases Of Investments | -1.06B | -781.35M | -292.24M | -19.24M | 0 | 0 |
Investments In Property Plant And Equipment | -77.50M | -72.66M | -58.45M | -14.67M | -3.99M | -5.30M |
Acquisitions Net | -13.69M | -25.67M | -41.78M | -106.89M | 0 | 0 |
Cash generated by investing activities | -221.10M | -352.62M | -332.24M | -119.78M | -5.77M | -5.30M |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 4.61M | 522.84M | 14.16K | 2.61M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -11.15K | 0 |
Repayments of term debt | 11.59M | 2.75M | -1.82M | -19.94M | 180.66K | -899K |
Cash used in financing activities | 10.35M | -1.62M | -3.88M | 683.65M | 194.82K | 12.18M |
Net Change In Cash | -254.04M | -86.49M | -92.97M | 586.56M | -2.89M | 10.44M |
Cash at end of period | 160.61M | 414.65M | 501.14M | 594.11M | 7.55M | 10.44M |
| Data source | Data source | Data source | Data source |